PESHAWAR: Research on coronavirus patients in the United States has found that two doses of Pfizer vaccine are effective against severe forms of the virus, including delta variants, for at least six months.
According to the AFP news agency, data from clinical trial shows that Pfizer vaccine can prevent a person infected with the coronavirus from hospitalisation. The study, published in the scientific journal Lancet, examines the effectiveness of vaccines in real-life settings over time. The research conducted by Kaiser Permanente has observed a record 3.4 million Southern California residents. One-third of the population had received full doses of the vaccine between December 2020 and August 2021.
After an average period of three to four months, those who completed the vaccine doses were up to 73% protected from the coronavirus, while 90% avoided hospitalization. Those who completed the vaccine dose were significantly safe from being hospitalised during the study despite being infected with any variant of the coronavirus. But the safety of the Delta variant was reduced by 40% within five months.
According to the study, the results are based on preliminary data from US and Israeli health officials, the decline in coronavirus immunity is “probably due to the Pfizer vaccine” debilitating effect, not because the vaccine cannot provide protection from the Delta variant.”
“Our findings underscore the importance of vaccine efficacy over time,” the study said. The results suggest that booster doses of the vaccine are more important for protection against the virus. In August, the US government approved an overdose of Covid-19 vaccines for people with weakened immune systems. In France, older people were being provided extra doses of the vaccine. Last month anther research also reported that the protection offered by Pfizer and AstraZeneca begins to fade in six months. The research conducted in the United Kingdom underscored the need for booster shots.